The IOL master is more accurate than A-scan immersion biometry in silicone oil (SO)-filled eyes.
The IOL master is more accurate than A-scan immersion biometry in silicone oil (SO)-filled eyes, claims a study in Eye.
Dr P. Kunavisarut et al., Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, conducted a prospective, consecutive, non-randomized investigation on 34 SO-filled eyes of 34 patients. All patients underwent a pars plana vitrectomy with SO removal and cataract surgery, as well as IOL implantation.
Axial length (AXL) was measured before SO removal using both A-scan immersion and IOL master. AXL was also measured three months after SO removal using IOL master. The accuracy of both techniques was determined by a mean postoperative AXL and reliability was determined by mean actual postoperative refractive error.
The preoperative mean AXL was 23.91±0.24 mm and 23.71±0.59 mm by the IOL master and A-scan immersion, respectively. The IOL master gave a postoperative mean AXL of 23.90±0.23 mm, which was statistically significant, compared with A-scan immersion.
At a range of −14.62 to 16.41 D predictive postoperative refractive error was greater in A-scan immersion, which was a statistically significant difference compared to the IOL master.
Overall, the IOL master is more accurate and has less deviation in predictive postoperative refractive error then A-scan immersion in SO-filled eyes.
The abstract can be read here.
AAO 2023: Company updates from Centricity Vision CEO Rob Thornhill
November 28th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.
AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials
November 24th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials